FDA nominee Overton to stress speed, efficiency to counter China in Senate hearing

Heidi Overton, nominee for FDA commissioner, will testify before the Senate emphasizing regulatory speed and efficiency as a competitive counter to China. This signals a potential shift toward faster drug approvals and a more China-focused regulatory posture, though specifics remain unclear. The outcome matters for pharmaceutical innovation and market access.